Low-dose angiostatic tyrosine kinase inhibitors improve photodynamic therapy for cancer: Lack of vascular normalization

Journal of Cellular and Molecular Medicine

Volumn 18, Issue 3, 2014, Pages 480-491

  Weiss, Andrea ^a,b   van Beijnum, Judy R ^b   Bonvin, Debora ^a   Jichlinski, Patrice ^c   Dyson, Paul J ^a   Griffioen, Arjan W ^b   Nowak Sliwinska, Patrycja ^b,c  

^a EPFL   (Switzerland)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Angiogenesis inhibitors; Axitinib, bevacizumab; Combination therapy; Endothelial cells; Photodynamic therapy; Sorafenib; Sunitinib; Synergy; Tyrosine kinase inhibitors

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; MONOCLONAL ANTIBODY; PROTEIN KINASE INHIBITOR;

ANIMAL; BLOOD VESSEL; CHICKEN; DOSE RESPONSE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MICROVASCULATURE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; PHOTOCHEMOTHERAPY; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL LINE; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; BLOOD VESSELS; CELL LINE, TUMOR; CHICKENS; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICROVESSELS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PHOTOCHEMOTHERAPY; PROTEIN KINASE INHIBITORS; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84894556756     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12199     Document Type: Article

References (46)

1. Agostinis P, Berg K, Cengel KA, et al. Photodynamic therapy of cancer: an update. CA Cancer J Clin. 2011; 61: 250-81.
2. Gomi F, Ohji M, Sayanagi K, et al. One-year outcomes of photodynamic therapy in age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patients. Ophthalmology. 2008; 115: 141-6.
3. Schmidt-Erfurth U, Hasan T. Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration. Surv Ophthalmol. 2000; 45: 195-214.
4. Weiss A, van den Bergh H, Griffioen AW, et al. Angiogenesis inhibition for the improvement of photodynamic therapy: the revival of a promising idea. BBA Rev Cancer. 2012; 1826: 53-70.
5. Nowak-Sliwinska P, Weiss A, Beijnum JR, et al. Angiostatic kinase inhibitors to sustain photodynamic angio-occlusion. J Cell Mol Med. 2012; 16: 1553-62.
6. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007; 356: 115-24.
7. Al-Husein B, Abdalla M, Trepte M, et al. Antiangiogenic therapy for cancer: an update. Pharmacotherapy. 2012; 32: 1095-111.
8. Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011; 364: 501-13.
9. Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011; 378: 1931-9.
10. Ibrahim N, Yu Y, Walsh WR, et al. Molecular targeted therapies for cancer: sorafenib mono-therapy and its combination with other therapies (review). Oncol Rep. 2012; 27: 1303-11.
11. Bukowski RM. Third generation tyrosine kinase inhibitors and their development in advanced renal cell carcinoma. Front Oncol. 2012; 2: 13.
12. Kessler ER, Bowles DW, Flaig TW, et al. Axitinib, a new therapeutic option in renal cell carcinoma. Drugs Today (Barc). 2012; 48: 633-44.
13. Sonpavde G, Hutson TE, Rini BI. Axitinib for renal cell carcinoma. Expert Opin Investig Drugs. 2008; 17: 741-8.
14. Antoszyk AN, Tuomi L, Chung CY, et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results. Am J Ophthalmol. 2008; 145: 862-74.
15. Bhuvaneswari R, Yuen GY, Chee SK, et al. Antiangiogenesis agents avastin and erbitux enhance the efficacy of photodynamic therapy in a murine bladder tumor model. Las Surg Med. 2011; 43: 651-62.
16. Fukumura D, Jain RK. Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization. Microvasc Res. 2007; 74: 72-84.
17. Lim SH, Nowak-Sliwinska P, Kamarulzaman FA, et al. The neovessel occlusion efficacy of 15-hydroxypurpurin-7-lactone dimethyl ester induced with photodynamic therapy. Photochem Photobiol. 2010; 86: 397-402.
18. Adar Y, Stark M, Bram EE, et al. Imidazoacridinone-dependent lysosomal photodestruction: a pharmacological Trojan horse approach to eradicate multidrug-resistant cancers. Cell Death Dis. 2012; 3: 1-10.
19. Reuwer AQ, Nowak-Sliwinska P, Mans LA, et al. Functional consequences of prolactin signaling in endothelial cells: a potential link with angiogenesis in pathophysiology? J Cell Mol Med. 2012; 16: 2035-48.
20. Nowak-Sliwinska P, Ballini J-P, Wagnières G, et al. Processing of fluorescence angiograms for the quantification of vascular effects induced by anti-angiogenic agents in the CAM model. Microvasc Res. 2010; 79: 21-8.
21. Romanoff AL. The Avian Embryo: structural and functional development. New York: McMillan; 1960.
22. Beckstead JH. A simple technique for preservation of fixation-sensitive antigens in paraffin-embedded tissues: addendum. J Histochem Cytochem. 1995; 43: 345.
23. Nowak-Sliwinska P, van Beijnum JR, van Berkel M, et al. Vascular regrowth following photodynamic therapy in the chicken embryo chorioallantoic membrane. Angiogenesis. 2010; 13: 281-92.
24. Nowak-Sliwinska P, Wagnieres G, van den Bergh H, et al. Angiostasis-induced vascular normalization can improve photodynamic therapy. Cell Mol Life Sci. 2010; 67: 1559-60.
25. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enz Reg. 1984; 22: 27-55.
26. van Beijnum JR, Nowak-Sliwinska P, van den Boezem E, et al. Tumor angiogenesis is enforced by autocrine regulation of high-mobility group box 1. Oncogene. 2013; 17: 363-74.
27. Schmidt-Erfurth U, Miller J, Sickenberg M, et al. Photodynamic therapy of subfoveal choroidal neovascularization: clinical and angiographic examples. Graefe's Arch Clin Exp Ophthal. 1998; 236: 365-74.
28. Yamashita A, Shiraga F, Shiragami C, et al. One-year results of reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol. 2010; 149: 465-71, e1.
29. del Carmen MG, Rizvi I, Chang Y, et al. Synergism of epidermal growth factor receptor-targeted immunotherapy with photodynamic treatment of ovarian cancer in vivo. J Natl Cancer Inst. 2005; 97: 1516-24.
30. Zhou Q, Olivo M, Lye KY, et al. Enhancing the therapeutic responsiveness of photodynamic therapy with the antiangiogenic agents SU5416 and SU6668 in murine nasopharyngeal carcinoma models. Cancer Chemother Pharmacol. 2005; 56: 569-77.
31. Dimitroff CJ, Klohs W, Sharma A, et al. Anti-angiogenic activity of selected receptor tyrosine kinase inhibitors, PD166285 and PD173074: implications for combination treatment with photodynamic therapy. Invest New Drugs. 1999; 17: 121-35.
32. Soler AM, Warloe T, Berner A, et al. A follow-up study of recurrence and cosmesis in completely responding superficial and nodular basal cell carcinomas treated with methyl 5-aminolaevulinate-based photodynamic therapy alone and with prior curettage. Br J Dermatol. 2001; 145: 467-71.
33. Basset-Seguin N, Ibbotson SH, Emtestam L, et al. Topical methyl aminolaevulinate photodynamic therapy versus cryotherapy for superficial basal cell carcinoma: a 5 year randomized trial. Eur J Dermatol. 2008; 18: 547-53.
34. Levendag PC, Meeuwis CA, Visser AG. Reirradiation of recurrent head and neck cancers: external and/or interstitial radiation therapy. Radiother Oncol. 1992; 23: 6-15.
35. Karakullukcu B, Nyst HJ, van Veen RL, et al. mTHPC mediated interstitial photodynamic therapy of recurrent nonmetastatic base of tongue cancers: development of a new method. Head Neck. 2012; 34: 1597-606.
36. Debefve E, Pegaz B, Ballini JP, et al. Combination therapy using verteporfin and ranibizumab; optimizing the timing in the CAM model. Photochem Photobiol. 2009; 85: 1400-8.
37. Porta C, Tortora G, Linassier C, et al. Maximising the duration of disease control in metastatic renal cell carcinoma with targeted agents: an expert agreement. Med Oncol. 2012; 29: 1896-907.
38. Papaetis GS, Syrigos KN. Sunitinib: a multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies. BioDrugs. 2009; 23: 377-89.
39. Gotink KJ, Verheul HM. Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action? Angiogenesis. 2010; 13: 1-14.
40. Kosharskyy B, Solban N, Chang SK, et al. A mechanism-based combination therapy reduces local tumor growth and metastasis in an orthotopic model of prostate cancer. Cancer Res. 2006; 66: 10953-8.
41. Ferrario A, Von Tiehl K, Wong S, et al. Cyclooxygenase-2 inhibitor treatment enhances photodynamic therapy-mediated tumor response. Cancer Res. 2002; 62: 3956-61.
42. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nature Med. 2001; 7: 987-9.
43. Dings RP, Loren M, Heun H, et al. Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization. Clin Cancer Res. 2007; 13: 3395-402.
44. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005; 307: 58-62.
45. Nieder C, Wiedenmann N, Andratschke N, et al. Current status of angiogenesis inhibitors combined with radiation therapy. Cancer Treat Rev. 2006; 32: 348-64.
46. Huber PE, Bischof M, Jenne J, et al. Trimodal cancer treatment: beneficial effects of combined antiangiogenesis, radiation, and chemotherapy. Cancer Res. 2005; 65: 3643-55.